Compare LFMD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | LRMR |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.5M | 276.7M |
| IPO Year | N/A | N/A |
| Metric | LFMD | LRMR |
|---|---|---|
| Price | $3.77 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $10.22 | ★ $16.71 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 03-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,091,814.00 | N/A |
| Revenue This Year | $13.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $3.18 | $1.61 |
| 52 Week High | $15.84 | $5.37 |
| Indicator | LFMD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 35.77 |
| Support Level | $3.84 | $3.12 |
| Resistance Level | $4.36 | $3.62 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 42.21 | 1.10 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.